Charles Schwab’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Charles Schwab’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,972	Closed	-$48.6K	–	3544
2023 Q4	$48.6K	Hold	15,972	–	–	﹤0.01%	3406
2023 Q3	$45.4K	Hold	15,972	–	–	﹤0.01%	3416
2023 Q2	$41.5K	Buy	+15,972	New	+$33.4K	﹤0.01%	3440
2022 Q2	–	Sell	-41,838	Closed	-$158K	–	3678
2022 Q1	$158K	Buy	41,838 +19,111	+84%	+$109K	﹤0.01%	3342
2021 Q4	$259K	Buy	22,727 +2,158	+10%	+$32.9K	﹤0.01%	3310
2021 Q3	$361K	Buy	+20,569	New	+$384K	﹤0.01%	3225

Other funds holding CYT

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFO

Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Charles Schwab's CYT Position: Q1 2024 in Review

Charles Schwab sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 15,972 shares — an estimated $48.6K sold.

Charles Schwab first reported a position in CYT in Q3 2021 and held it in 6 quarters. The position peaked at $361K in Q3 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

Charles Schwab reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Charles Schwab sold 15,972 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $48.6K.
Charles Schwab first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Charles Schwab's Cyteir Therapeutics, Inc. Common Stock position peaked at $361K in Q3 2021.
4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.